The FDA has added a new warning to the labels of several weight loss drugs, Wegovy among them. The full report has the details of what changed.
Recap by typeshit. Full story at Philstar Life.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
Holly Lofton and Jennifer Manne-Goehler say safety looks similar to other GLP-1s so far, and Lofton reports gray market patients who saw no weight loss at all.
Analysts expect a launch around 100,000 won a month, about half of Wegovy's starting price. Its 9.02% average weight loss over 40 weeks trails Mounjaro and Wegovy.
Loading…